KR101072885B1 - 비만치료방법 - Google Patents
비만치료방법 Download PDFInfo
- Publication number
- KR101072885B1 KR101072885B1 KR1020047018476A KR20047018476A KR101072885B1 KR 101072885 B1 KR101072885 B1 KR 101072885B1 KR 1020047018476 A KR1020047018476 A KR 1020047018476A KR 20047018476 A KR20047018476 A KR 20047018476A KR 101072885 B1 KR101072885 B1 KR 101072885B1
- Authority
- KR
- South Korea
- Prior art keywords
- composition
- pharmaceutically acceptable
- acceptable salt
- compound
- bupropion
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7024—Esters of saccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Emergency Medicine (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Child & Adolescent Psychology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
특 성 | 조니스아미드(N=30) | 위약(N=30) |
나이(년) | 37.5(1.3) | 36.4(1.6) |
성별 남 여 |
5 25 |
0 30 |
인 종 흑인 백인 |
12 18 |
17 13 |
체중(kg) | 98.2(2.5) | 97.8(2.6) |
BMI(kg/m2) | 35.4(0.7) | 37.2(0.8) |
체지방(%) | 40.8(0.9) | 42.6(0.8) |
Claims (49)
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 과체중 또는 비만의 사람의 체중을 감량하기 위하여 이러한 감량에 효과를 나타내기에 충분한 양으로 제1 화합물과 제2 화합물을 함유하는 조성물로서,상기 제1 화합물이 하기 식(III)의 체중-감량 촉진 진경제(anticonvulsant)이고:상기 식에서,R1은 수소 또는 할로겐 원자이고,R2 및 R3는 동일하거나 다르고 각각 수소 또는 1 내지 3의 탄소 원자를 가지는 알킬기이며,X 및 Y 중 하나는 탄소 원자이고 다른 하나는 질소원자(단, 상기 -CH2SO2NR2R3은 X 및 Y중 어느 하나의 탄소 원자에 결합한다)이거나 또는 이의 알칼리 금속염이며,상기 제2 화합물은 부프로피온, 아토목세틴, 및 레보제틴으로 구성된 군으로부터 선택되는 조성물.
- 제13항에 있어서, 상기 제1 화합물이 조니스아미드 또는 이의 약제학적 허용 염인 조성물.
- 제13항에 있어서, 상기 제2 화합물이 부프로피온 또는 이의 약제학적 허용 염인 조성물.
- 제15항에 있어서, 상기 제1 화합물이 조니스아미드 또는 이의 약제학적 허용 염인 조성물.
- 제15항에 있어서, 상기 부프로피온 또는 이의 약제학적 허용 염이 서방성 제제(sustained release formulation)인 조성물.
- 제14항에 있어서, 상기 조니스아미드 또는 이의 약제학적 허용 염이 서방성 제제인 조성물.
- 제16항에 있어서, 상기 부프로피온 또는 이의 약제학적 허용 염 및 조니스아미드 또는 이의 약제학적 허용 염 중 적어도 하나는 서방성 제제인 조성물.
- 제13항 내지 제19항 중 어느 한 항에 있어서, 상기 조성물은 투여 단위제형(dosage unit form)으로 투여되는 조성물.
- 제20항에 있어서, 상기 조성물은 정제 또는 캡슐의 형태로 되는 조성물.
- 제13항 내지 제19항 중 어느 한 항에 있어서, 상기 제1 화합물 및 상기 제2 화합물이 개별적으로 투여될 수 있도록 하기 위하여 상기 조성물이 배열되는 조성물.
- 제15항 내지 제17항, 및 제19항 중 어느 한 항에 있어서, 상기 부프로피온 또는 이의 약제학적 허용 염의 양이 25 mg 내지 600 mg인 조성물.
- 제15항 내지 제17항, 및 제19항 중 어느 한 항에 있어서, 상기 부프로피온 또는 이의 약제학적 허용 염의 양이 50 mg 내지 450 mg인 조성물.
- 제14항, 제16항, 제18항 및 제19항 중 어느 한 항에 있어서, 상기 조니스아미드 또는 이의 약제학적 허용 염의 양이 25 mg 내지 800 mg인 조성물.
- 제23항에 있어서, 상기 조니스아미드 또는 이의 약제학적 허용 염의 양이 25 mg 내지 800 mg인 조성물.
- 제24항에 있어서, 상기 조니스아미드 또는 이의 약제학적 허용 염의 양이 25 mg 내지 800 mg인 조성물.
- 제14항, 제16항, 제18항 및 제19항 중 어느 한 항에 있어서, 상기 조니스아미드 또는 이의 약제학적 허용 염의 양이 100 mg 내지 600 mg인 조성물.
- 고혈압, 당뇨병 또는 이상지혈증(dyslipidaemia)의 위험을 감소시키기 위하여 이러한 감소에 효과를 나타내기에 충분한 양으로 제1 화합물과 제2 화합물을 함유하는 조성물로서,상기 제1 화합물이 하기 식(III)의 체중-감량 촉진 진경제(anticonvulsant)이고:상기 식에서,R1은 수소 또는 할로겐 원자이고,R2 및 R3는 동일하거나 다르고 각각 수소 또는 1 내지 3의 탄소 원자를 가지는 알킬기이며,X 및 Y 중 하나는 탄소 원자이고 다른 하나는 질소원자(단, 상기 -CH2SO2NR2R3은 X 및 Y중 어느 하나의 탄소 원자에 결합한다)이거나 또는 이의 알칼리 금속염이며,상기 제2 화합물은 부프로피온, 아토목세틴, 및 레보제틴으로 구성된 군으로부터 선택되는 조성물.
- 제29항에 있어서, 상기 제1 화합물이 조니스아미드 또는 이의 약제학적 허용 염인 조성물.
- 제29항에 있어서, 상기 제2 화합물이 부프로피온 또는 이의 약제학적 허용 염인 조성물.
- 제31항에 있어서, 상기 제1 화합물이 조니스아미드 또는 이의 약제학적 허용 염인 조성물.
- 제31항에 있어서, 상기 부프로피온 또는 이의 약제학적 허용 염이 서방성 제제(sustained release formulation)인 조성물.
- 제30항에 있어서, 상기 조니스아미드 또는 이의 약제학적 허용 염이 서방성 제제인 조성물.
- 제32항에 있어서, 상기 부프로피온 또는 이의 약제학적 허용 염 및 조니스아미드 또는 이의 약제학적 허용 염 중 적어도 하나는 서방성 제제인 조성물.
- 제29항 내지 제35항 중 어느 한 항에 있어서, 상기 조성물은 투여 단위제형(dosage unit form)으로 투여되는 조성물.
- 제36항에 있어서, 상기 조성물은 정제 또는 캡슐의 형태로 되는 조성물.
- 제29항 내지 제35항 중 어느 한 항에 있어서, 상기 제1 화합물 및 상기 제2 화합물이 개별적으로 투여될 수 있도록 하기 위하여 상기 조성물이 배열되는 조성물.
- 제31항 내지 제33항, 및 제35항 중 어느 한 항에 있어서, 상기 부프로피온 또는 이의 약제학적 허용 염의 양이 25 mg 내지 600 mg인 조성물.
- 제31항 내지 제33, 및 제35항 중 어느 한 항에 있어서, 상기 부프로피온 또는 이의 약제학적 허용 염의 양이 50 mg 내지 450 mg인 조성물.
- 제30항, 제32항, 제34항 및 제35항 중 어느 한 항에 있어서, 상기 조니스아미드 또는 이의 약제학적 허용 염의 양이 25 mg 내지 800 mg인 조성물.
- 제39항에 있어서, 상기 조니스아미드 또는 이의 약제학적 허용 염의 양이 25 mg 내지 800 mg인 조성물.
- 제40항에 있어서, 상기 조니스아미드 또는 이의 약제학적 허용 염의 양이 25 mg 내지 800 mg인 조성물.
- 제30항, 제32항, 제34항 및 제35항 중 어느 한 항에 있어서, 상기 조니스아미드 또는 이의 약제학적 허용 염의 양이 100 mg 내지 600 mg인 조성물.
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US38087402P | 2002-05-17 | 2002-05-17 | |
US60/380,874 | 2002-05-17 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020117003379A Division KR20110043664A (ko) | 2002-05-17 | 2003-05-19 | 비만치료방법 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20050023265A KR20050023265A (ko) | 2005-03-09 |
KR101072885B1 true KR101072885B1 (ko) | 2011-10-17 |
Family
ID=29550030
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020047018476A KR101072885B1 (ko) | 2002-05-17 | 2003-05-19 | 비만치료방법 |
KR1020117003379A KR20110043664A (ko) | 2002-05-17 | 2003-05-19 | 비만치료방법 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020117003379A KR20110043664A (ko) | 2002-05-17 | 2003-05-19 | 비만치료방법 |
Country Status (11)
Country | Link |
---|---|
US (7) | US7109198B2 (ko) |
EP (3) | EP3173082A1 (ko) |
JP (1) | JP4545584B2 (ko) |
KR (2) | KR101072885B1 (ko) |
CN (1) | CN1320886C (ko) |
AU (1) | AU2003231788B2 (ko) |
CA (1) | CA2483464C (ko) |
HK (1) | HK1074778A1 (ko) |
MX (1) | MXPA04011203A (ko) |
RU (1) | RU2341259C2 (ko) |
WO (1) | WO2003097046A1 (ko) |
Families Citing this family (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080255093A1 (en) * | 1999-06-14 | 2008-10-16 | Tam Peter Y | Compositions and methods for treating obesity and related disorders |
US7674776B2 (en) | 1999-06-14 | 2010-03-09 | Vivus, Inc. | Combination therapy for effecting weight loss and treating obesity |
US20080103179A1 (en) * | 2006-10-27 | 2008-05-01 | Tam Peter Y | Combination Therapy |
US20040029941A1 (en) * | 2002-05-06 | 2004-02-12 | Jennings Julianne E. | Zonisamide use in obesity and eating disorders |
US20190262318A1 (en) * | 2002-05-17 | 2019-08-29 | Duke University | Method for Treating Obesity |
KR101072885B1 (ko) * | 2002-05-17 | 2011-10-17 | 듀크 유니버시티 | 비만치료방법 |
US20190290618A1 (en) * | 2002-05-17 | 2019-09-26 | Duke University | Method for Treating Obesity |
US20050215552A1 (en) * | 2002-05-17 | 2005-09-29 | Gadde Kishore M | Method for treating obesity |
US20050059718A1 (en) * | 2003-02-21 | 2005-03-17 | Hayato Miyachi | Methods of using zonisamide as an adjunctive therapy for partial seizures |
PT2316456T (pt) | 2003-04-29 | 2017-09-05 | Orexigen Therapeutics Inc | Composições para afetar a perda de peso compreendendo naltrexona e bupropion |
US20050043704A1 (en) * | 2003-08-21 | 2005-02-24 | Eisai Co., Ltd | Methods of using zonisamide as an adjunctive therapy for partial seizures |
US20050043773A1 (en) * | 2003-08-21 | 2005-02-24 | Ivan Lieberburg | Methods of improving the safety of zonisamide therapy |
US20050154032A1 (en) * | 2004-01-08 | 2005-07-14 | Eisai Co., Ltd | Methods of using zonisamide as an adjunctive therapy for partial seizures |
US20050154034A1 (en) * | 2004-01-08 | 2005-07-14 | Eisai Co., Ltd. | Methods of using zonisamide as an adjunctive therapy for partial seizures |
US20050154033A1 (en) * | 2004-01-08 | 2005-07-14 | Eisai Co., Ltd | Methods of using zonisamide as an adjunctive therapy for partial seizures |
US20050154037A1 (en) * | 2004-01-09 | 2005-07-14 | Eisai Co., Ltd. | Methods of using zonisamide as an adjunctive therapy for partial seizures |
US20050154036A1 (en) * | 2004-01-09 | 2005-07-14 | Eisai Co., Ltd. | Methods of using zonisamide as an adjunctive therapy for partial seizures |
US7713959B2 (en) | 2004-01-13 | 2010-05-11 | Duke University | Compositions of an anticonvulsant and mirtazapine to prevent weight gain |
CA2553207A1 (en) | 2004-01-13 | 2005-08-04 | Kishore M. Gadde | Compositions of an anticonvulsant and an antipsychotic drug for affecting weight loss |
US20060160750A1 (en) * | 2004-01-13 | 2006-07-20 | Krishnan K R R | Compositions of an anticonvulsant and an antipsychotic drug and methods of using the same for affecting weight loss |
SE0400378D0 (sv) * | 2004-02-17 | 2004-02-17 | Jan Hedner | Sätt att behandla och diagnostisera andningsstörningar i sömnen och medel för att utföra sättet |
US20060100205A1 (en) * | 2004-04-21 | 2006-05-11 | Eckard Weber | Compositions for affecting weight loss |
CA2565154A1 (en) * | 2004-05-03 | 2005-11-24 | Duke University | Compositions for affecting weight loss |
US20060153934A1 (en) * | 2005-01-13 | 2006-07-13 | Navitas Pharma | Combination therapies of cicletanine and magnesium |
US20060276412A1 (en) * | 2005-05-31 | 2006-12-07 | Gary Tollefson | Methods and compositions for managing psychotic disorders |
RU2408368C2 (ru) * | 2005-06-27 | 2011-01-10 | Биовэйл Лэборэториз Интернэшнл С.Р.Л. | Препараты соли бупропиона с модифицированным высвобождением |
JP4903796B2 (ja) | 2005-08-17 | 2012-03-28 | ヒルズ・ペット・ニュートリシャン・インコーポレーテッド | 腎疾患の予防及び治療のための方法及び組成物 |
US20070077310A1 (en) * | 2005-10-03 | 2007-04-05 | University Of Tennessee Research Foundation | Methods of reducing the production of reactive oxygen species and methods of screening or identifying compounds and compositions that reduce the production of reactive oxygen species |
WO2007047351A2 (en) * | 2005-10-13 | 2007-04-26 | Orexigen Therapeutics, Inc. | Methods for treating hypertension in overweight and obese individuals |
JP5180092B2 (ja) | 2005-11-22 | 2013-04-10 | オレキシジェン・セラピューティクス・インコーポレーテッド | インスリン感受性を増すための組成物および方法 |
WO2007089318A2 (en) * | 2005-11-23 | 2007-08-09 | Orexigen Therapeutics, Inc. | Compositions and methods for reducing food cravings |
DK1954241T3 (da) * | 2005-11-28 | 2012-06-18 | Orexigen Therapeutics Inc | Zonisamid-formulering med vedvarende frigivelse |
US8916195B2 (en) | 2006-06-05 | 2014-12-23 | Orexigen Therapeutics, Inc. | Sustained release formulation of naltrexone |
US8748419B2 (en) * | 2006-06-16 | 2014-06-10 | Theracos, Inc. | Treating obesity with muscarinic receptor M1 antagonists |
CN101588795A (zh) * | 2006-11-09 | 2009-11-25 | 奥雷西根治疗公司 | 包含中间快速溶解层的分层药物制剂 |
AU2007319472B2 (en) | 2006-11-09 | 2013-01-17 | Nalpropion Pharmaceuticals Llc | Methods Of Administering Weight Loss Medications |
MX2010012909A (es) | 2008-05-30 | 2011-02-25 | Orexigen Therapeutics Inc | Metodos para tratamiento de condiciones de grasa visceral. |
US8580298B2 (en) | 2008-06-09 | 2013-11-12 | Vivus, Inc. | Low dose topiramate/phentermine composition and methods of use thereof |
US20090304789A1 (en) * | 2008-06-09 | 2009-12-10 | Thomas Najarian | Novel topiramate compositions and an escalating dosing strategy for treating obesity and related disorders |
WO2009152152A1 (en) * | 2008-06-09 | 2009-12-17 | Amarillo Biosciences, Inc. | Treatment of obesity with an interferon |
US8114445B2 (en) * | 2008-11-07 | 2012-02-14 | Reliv International Inc. | Dietary supplement for promoting wellness and weight loss and methods of administering the same |
WO2010078301A1 (en) * | 2008-12-30 | 2010-07-08 | Hill's Pet Nutrition, Inc. | Compositions and methods for treating and preventing weight-related disorders in companion animals |
WO2011084371A1 (en) * | 2009-12-21 | 2011-07-14 | Merck Sharp & Dohme Corp. | Aminobenzoquinazolinone m1 receptor positive allosteric modulators |
EP3659604A1 (en) | 2010-01-11 | 2020-06-03 | Nalpropion Pharmaceuticals, Inc. | Methods of providing weight loss therapy in patients with major depression |
US8440655B2 (en) | 2010-06-21 | 2013-05-14 | Theracos, Inc. | Combination therapy for the treatment of diabetes |
WO2012111011A2 (en) | 2011-02-16 | 2012-08-23 | Nir Barak | Low dosage combinations of fluoxetine and reboxetine for treating obesity |
WO2013012760A1 (en) | 2011-07-15 | 2013-01-24 | Numeta Sciences, Inc. | Compositions and methods for modulating metabolic pathways |
US9198454B2 (en) | 2012-03-08 | 2015-12-01 | Nusirt Sciences, Inc. | Compositions, methods, and kits for regulating energy metabolism |
HUE049859T2 (hu) | 2012-06-06 | 2020-10-28 | Nalpropion Pharmaceuticals Llc | Készítmény magas kardiovaszkuláris kockázatnak kitett páciensekben túlsúly és elhízás kezelésére szolgáló eljárásban történõ alkalmazásra |
CA2891335C (en) | 2012-11-13 | 2021-05-04 | Nusirt Sciences, Inc. | Compositions and methods for increasing energy metabolism |
AU2014207707B2 (en) | 2013-01-15 | 2018-11-01 | Nusirt Sciences, Inc. | Treating pulmonary conditions |
US8652527B1 (en) | 2013-03-13 | 2014-02-18 | Upsher-Smith Laboratories, Inc | Extended-release topiramate capsules |
US9101545B2 (en) | 2013-03-15 | 2015-08-11 | Upsher-Smith Laboratories, Inc. | Extended-release topiramate capsules |
CA2902879C (en) | 2013-03-15 | 2023-09-26 | Nusirt Sciences, Inc. | Leucine and nicotinic acid reduces lipid levels |
US8969371B1 (en) | 2013-12-06 | 2015-03-03 | Orexigen Therapeutics, Inc. | Compositions and methods for weight loss in at risk patient populations |
KR20160119863A (ko) | 2014-02-27 | 2016-10-14 | 뉴서트 사이언시스, 인크. | 간 지방증의 감소 또는 예방을 위한 조성물 및 방법 |
US10278948B1 (en) | 2015-09-03 | 2019-05-07 | Tian Xia | Method for transnasal delivery of anticonvulsant and therapeutic treatments |
WO2019038584A1 (en) | 2017-08-19 | 2019-02-28 | Ftf Pharma Private Limited | ORAL PHARMACEUTICAL COMPOSITION COMPRISING ZONISAMIDE AND PREPARATION METHOD THEREOF |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001026641A2 (en) * | 1999-10-13 | 2001-04-19 | Glaxo Group Limited | Morpholinol derivatives for the treatment of obesity |
Family Cites Families (103)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US122033A (en) * | 1871-12-19 | Improvement in rotary engines | ||
US100205A (en) * | 1870-02-22 | Improvement in furnaces | ||
US33965A (en) * | 1861-12-17 | Improvement in rifle-sights | ||
US142290A (en) * | 1873-08-26 | Improvement in trimming attachments for sewing-machines | ||
US9514A (en) * | 1853-01-04 | Improvement in self-winding telegraphic registers | ||
US137144A (en) * | 1873-03-25 | Improvement in stop-cocks | ||
US215552A (en) * | 1879-05-20 | Improvement in gar-couplings | ||
US79501A (en) * | 1868-06-30 | Jambs righey | ||
US58293A (en) * | 1866-09-25 | Improved lady s-saddle tree | ||
US181070A (en) * | 1876-08-15 | Improvement in burglar-proof gratings | ||
US26986A (en) * | 1860-01-31 | Mortising-machine | ||
US143322A (en) * | 1873-09-30 | blake | ||
US154002A (en) * | 1874-08-11 | Improvement in electric telegraphs | ||
US106576A (en) * | 1870-08-23 | Improvement in washing-machines | ||
US277579A (en) * | 1883-05-15 | Axle-skein | ||
US2462A (en) * | 1842-02-21 | Worked buttons on the heads | ||
US254208A (en) * | 1882-02-28 | Geoegb e | ||
US55008A (en) * | 1866-05-22 | Improved clothes-sprinkler | ||
US144174A (en) * | 1873-10-28 | Improvement in steam-engine valve-gears | ||
US160750A (en) * | 1875-03-16 | Improvement in grain-separators | ||
US3885046A (en) | 1969-12-04 | 1975-05-20 | Burroughs Wellcome Co | Meta chloro or fluoro substituted alpha-T-butylaminopropionphenones in the treatment of depression |
BE759838A (fr) | 1969-12-04 | 1971-06-03 | Wellcome Found | Cetones a activite biologique |
US4089855A (en) | 1976-04-23 | 1978-05-16 | Cornell Research Foundation, Inc. | Process for the stereoselective reduction of 6- and 8-keto morphine and morphinan derivatives with formamidinesulfinic acid and compounds obtained thereby |
US4172896A (en) | 1978-06-05 | 1979-10-30 | Dainippon Pharmaceutical Co., Ltd. | Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same |
US4513006A (en) | 1983-09-26 | 1985-04-23 | Mcneil Lab., Inc. | Anticonvulsant sulfamate derivatives |
US4689332A (en) | 1984-04-09 | 1987-08-25 | Research Corporation | Growth regulation and related applications of opioid antagonists |
US5266574A (en) | 1984-04-09 | 1993-11-30 | Ian S. Zagon | Growth regulation and related applications of opioid antagonists |
US4673679A (en) | 1986-05-14 | 1987-06-16 | E. I. Du Pont De Nemours And Company | Use of prodrugs of 3-hydroxymorphinans to prevent bitter taste upon buccal, nasal or sublingual administration |
NL8800823A (nl) | 1987-04-10 | 1988-11-01 | Sandoz Ag | Werkwijze voor het toepassen van dopamine-receptor agonisten en farmaceutische preparaten die deze agonisten bevatten. |
US5719197A (en) * | 1988-03-04 | 1998-02-17 | Noven Pharmaceuticals, Inc. | Compositions and methods for topical administration of pharmaceutically active agents |
WO1990013294A1 (en) | 1989-05-09 | 1990-11-15 | Whitby Research, Inc. | A method of reducing body weight and food intake using a dopamine d2 receptor agonist |
FR2657350B1 (fr) | 1990-01-19 | 1992-05-15 | Centre Nat Rech Scient | Composes destines a l'encapsulation dans les erythrocytes - nouveaux derives de la naloxone et naltrexone. |
US5486362A (en) | 1991-05-07 | 1996-01-23 | Dynagen, Inc. | Controlled, sustained release delivery system for treating drug dependency |
US5403595A (en) | 1991-05-07 | 1995-04-04 | Dynagen, Inc. | Controlled, sustained release delivery system for smoking cessation |
GB9217295D0 (en) | 1992-08-14 | 1992-09-30 | Wellcome Found | Controlled released tablets |
US5312925A (en) | 1992-09-01 | 1994-05-17 | Pfizer Inc. | Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride |
US5512593A (en) | 1993-03-02 | 1996-04-30 | John S. Nagle | Composition and method of treating depression using natoxone or naltrexone in combination with a serotonin reuptake inhibitor |
US5541231A (en) | 1993-07-30 | 1996-07-30 | Glaxo Wellcome Inc. | Stabilized Pharmaceutical |
US5358970A (en) | 1993-08-12 | 1994-10-25 | Burroughs Wellcome Co. | Pharmaceutical composition containing bupropion hydrochloride and a stabilizer |
GB9315856D0 (en) | 1993-07-30 | 1993-09-15 | Wellcome Found | Stabilized pharmaceutical |
DE69525847T2 (de) | 1994-09-19 | 2002-09-05 | Dupont Pharmaceuticals Co., Wilmington | Zusammensetzungen von opioid antagonisten mit selektiven serotonin-aufnahme inhibitoren, zur behandlung von alkoholismus und alkohoabhängigkeit |
US5713488A (en) * | 1996-01-24 | 1998-02-03 | Farrugia; John V. | Condom dispenser |
CA2220768A1 (en) | 1996-03-13 | 1997-09-18 | Yale University | Smoking cessation treatments using naltrexone and related compounds |
US20040024006A1 (en) | 1996-05-06 | 2004-02-05 | Simon David Lew | Opioid pharmaceutical compositions |
ATE224189T1 (de) | 1996-06-28 | 2002-10-15 | Ortho Mcneil Pharm Inc | Antikonvulsive sulfamatderivate zur behandlung von fettleibigkeit |
FR2758723B1 (fr) | 1997-01-28 | 1999-04-23 | Sanofi Sa | Utilisation des antagonistes des recepteurs aux cannabinoides centraux pour la preparation de medicaments |
CN1155410C (zh) | 1997-10-03 | 2004-06-30 | 卡里药品公司 | 治疗尼古丁成瘾的含有尼古丁受体拮抗剂和抗抑郁药或抗焦虑药的组合物 |
US6262049B1 (en) * | 1997-10-28 | 2001-07-17 | Schering Corporation | Method of reducing nicotine and tobacco craving in mammals |
IL127497A (en) | 1997-12-18 | 2002-07-25 | Pfizer Prod Inc | Medicinal products containing piperazinyl-heterocyclic compounds for the treatment of psychiatric disorders |
WO1999033465A1 (en) * | 1997-12-26 | 1999-07-08 | Dainippon Pharmaceutical Co., Ltd. | Remedy for neurodegenerative diseases___________________________ |
BR9907203A (pt) | 1998-01-21 | 2000-10-17 | Glaxo Group Ltd | "composto, composições farmacêuticas, uso de um composto, e, processo de tratametno de depressão, distúrbio de hiperatividade por deficiência de atenção (adhd), obesidade, enxaqueca, dor, disfunção sexual, doença de parkinson, doença de alzeheimer, ou vìcio de cocaìna ou de produtos contendo nicotina (especialmente tabaco) em um indivìduo animal ou humano. " |
AU2483599A (en) | 1998-01-29 | 1999-08-16 | Sepracor, Inc. | Pharmaceutical uses of optically pure (-)-bupropion |
US6048322A (en) * | 1998-04-15 | 2000-04-11 | Kushida; Clete | Morphometric measurement tool |
US6150366A (en) | 1998-06-15 | 2000-11-21 | Pfizer Inc. | Ziprasidone formulations |
US20030144174A1 (en) | 1998-12-09 | 2003-07-31 | Miles B. Brennan | Methods for identifying compounds useful for the regulation of body weight and associated conditions |
DK1158973T3 (da) * | 1999-02-24 | 2005-05-30 | Univ Cincinnati | Anvendelse af sulfamatderivater til behandling af impulskontrolafvigelser |
US8545880B2 (en) | 1999-02-26 | 2013-10-01 | Andrx Pharmaceuticals, Llc | Controlled release oral dosage form |
US6210716B1 (en) | 1999-02-26 | 2001-04-03 | Andrx Pharmaceuticals, Inc. | Controlled release bupropion formulation |
US6248363B1 (en) | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
US6337328B1 (en) | 1999-03-01 | 2002-01-08 | Sepracor, Inc. | Bupropion metabolites and methods of use |
US6342496B1 (en) | 1999-03-01 | 2002-01-29 | Sepracor Inc. | Bupropion metabolites and methods of use |
US6267995B1 (en) | 1999-03-03 | 2001-07-31 | Pure World Botanicals, Inc. | Extract of Lepidium meyenii roots for pharmaceutical applications |
WO2000059855A1 (en) * | 1999-04-01 | 2000-10-12 | Esperion Therapeutics, Inc. | Ether compounds, compositions, and uses thereof |
ES2305606T3 (es) | 1999-04-06 | 2008-11-01 | Sepracor Inc. | Succinato de o-desmetilvenlafaxina. |
US6420369B1 (en) | 1999-05-24 | 2002-07-16 | Ortho-Mcneil Pharmaceutical, Inc. | Anticonvulsant derivatives useful in treating dementia |
US7056890B2 (en) | 1999-06-14 | 2006-06-06 | Vivus, Inc. | Combination therapy for effecting weight loss and treating obesity |
EP1187603B1 (en) | 1999-06-14 | 2007-08-08 | Vivus, Inc. | Combination therapy for effecting weight loss and treating obesity |
ATE305307T1 (de) * | 1999-07-01 | 2005-10-15 | Pharmacia & Upjohn Co Llc | Reboxetin zur behandlung von migränekopfschmerzen |
US6071918A (en) | 1999-07-21 | 2000-06-06 | Dupont Pharmaceuticals Company | Combination of an opioid antagonist and a selective serotonin reuptake inhibitor for treatment of alcoholism and alcohol dependence |
US6403657B1 (en) | 1999-10-04 | 2002-06-11 | Martin C. Hinz | Comprehensive pharmacologic therapy for treatment of obesity |
GB2355191A (en) | 1999-10-12 | 2001-04-18 | Laxdale Ltd | Combination formulations for fatigue, head injury and strokes |
CN1406129A (zh) | 2000-01-22 | 2003-03-26 | 艾伯特·舒尔曼 | 用于治疗物质滥用的方法 |
US20020090615A1 (en) | 2000-01-31 | 2002-07-11 | Rosen Craig A. | Nucleic acids, proteins, and antibodies |
DE60119696T2 (de) | 2000-03-15 | 2007-01-25 | Wolfgang Ross Sadee | Naloxon- und naltrexon-analoga in der behandlung bei drogenmissbrauch |
US6437147B1 (en) * | 2000-03-17 | 2002-08-20 | Novo Nordisk | Imidazole compounds |
US6191117B1 (en) | 2000-07-10 | 2001-02-20 | Walter E. Kozachuk | Methods of producing weight loss and treatment of obesity |
WO2002009694A1 (en) * | 2000-08-02 | 2002-02-07 | Ortho-Mcneil Pharmaceutical, Inc. | Anticonvulsant derivatives useful for the treatment of depression |
EP1970072A1 (en) | 2000-09-18 | 2008-09-17 | Sanos Bioscience A/S | Use of GLP-2 peptides for the treatment of hyperparathyroidism |
WO2002064210A2 (en) | 2000-10-30 | 2002-08-22 | Ortho-Mcneil Pharmaceutical, Inc. | Combination therapy comprising anti-diabetic and anticonvulsant agents |
US6569449B1 (en) | 2000-11-13 | 2003-05-27 | University Of Kentucky Research Foundation | Transdermal delivery of opioid antagonist prodrugs |
US20030087896A1 (en) | 2001-08-09 | 2003-05-08 | Hillel Glover | Treatment of refractory depression with an opiate antagonist and an antidepressant |
US6481031B1 (en) * | 2001-11-14 | 2002-11-19 | In Mo Hwang | Pillow oriented for comfort in varying sleeping positions |
US20040029941A1 (en) | 2002-05-06 | 2004-02-12 | Jennings Julianne E. | Zonisamide use in obesity and eating disorders |
KR101072885B1 (ko) | 2002-05-17 | 2011-10-17 | 듀크 유니버시티 | 비만치료방법 |
US20050215552A1 (en) | 2002-05-17 | 2005-09-29 | Gadde Kishore M | Method for treating obesity |
EP1534074A4 (en) | 2002-07-18 | 2008-01-09 | Merck & Co Inc | POLYTHERAPY FOR THE TREATMENT OF OBESITY |
WO2004024096A2 (en) | 2002-09-13 | 2004-03-25 | Eisai Co., Ltd. | Method of treating tremors |
US20040122033A1 (en) | 2002-12-10 | 2004-06-24 | Nargund Ravi P. | Combination therapy for the treatment of obesity |
PT2316456T (pt) | 2003-04-29 | 2017-09-05 | Orexigen Therapeutics Inc | Composições para afetar a perda de peso compreendendo naltrexona e bupropion |
WO2005000217A2 (en) | 2003-06-06 | 2005-01-06 | Merck & Co., Inc. | Combination therapy for the treatment of dyslipidemia |
WO2004110375A2 (en) | 2003-06-06 | 2004-12-23 | Merck & Co., Inc. | Combination therapy for the treatment of diabetes |
US20060160834A1 (en) | 2003-06-06 | 2006-07-20 | Fong Tung M | Combination therapy for the treatment of hypertension |
US7759358B2 (en) | 2003-07-23 | 2010-07-20 | Crooks Peter A | Oral bioavailable prodrugs |
KR100965580B1 (ko) * | 2003-08-21 | 2010-06-23 | 엘지디스플레이 주식회사 | 액정표시장치와 그의 구동방법 |
WO2005049043A1 (en) | 2003-11-18 | 2005-06-02 | Ortho-Mcneil Pharmaceutical, Inc. | Combination therapy comprising metformin and anticonvulsant agents |
US7713959B2 (en) | 2004-01-13 | 2010-05-11 | Duke University | Compositions of an anticonvulsant and mirtazapine to prevent weight gain |
CA2553207A1 (en) | 2004-01-13 | 2005-08-04 | Kishore M. Gadde | Compositions of an anticonvulsant and an antipsychotic drug for affecting weight loss |
US20060160750A1 (en) | 2004-01-13 | 2006-07-20 | Krishnan K R R | Compositions of an anticonvulsant and an antipsychotic drug and methods of using the same for affecting weight loss |
US20060100205A1 (en) | 2004-04-21 | 2006-05-11 | Eckard Weber | Compositions for affecting weight loss |
CA2565154A1 (en) | 2004-05-03 | 2005-11-24 | Duke University | Compositions for affecting weight loss |
US20060058293A1 (en) | 2004-08-03 | 2006-03-16 | Eckard Weber | Combination of bupropion and a second compound for affecting weight loss |
WO2006055854A2 (en) * | 2004-11-17 | 2006-05-26 | Cypress Bioscience, Inc. | Methods for reducing the side effects associated with mirtazapine treatment |
US7346233B2 (en) * | 2005-02-14 | 2008-03-18 | Corning Incorporated | Single mode (SM) fiber optical reader system and method for interrogating resonant waveguide-grating sensor(s) |
-
2003
- 2003-05-19 KR KR1020047018476A patent/KR101072885B1/ko active IP Right Grant
- 2003-05-19 WO PCT/US2003/015703 patent/WO2003097046A1/en active Application Filing
- 2003-05-19 AU AU2003231788A patent/AU2003231788B2/en not_active Expired
- 2003-05-19 CN CNB038112299A patent/CN1320886C/zh not_active Expired - Lifetime
- 2003-05-19 EP EP16178084.6A patent/EP3173082A1/en not_active Withdrawn
- 2003-05-19 CA CA2483464A patent/CA2483464C/en not_active Expired - Lifetime
- 2003-05-19 KR KR1020117003379A patent/KR20110043664A/ko not_active Application Discontinuation
- 2003-05-19 EP EP03753096.1A patent/EP1505967B1/en not_active Expired - Lifetime
- 2003-05-19 EP EP10185789A patent/EP2301537A1/en not_active Ceased
- 2003-05-19 RU RU2004131636/14A patent/RU2341259C2/ru active
- 2003-05-19 US US10/440,404 patent/US7109198B2/en not_active Expired - Lifetime
- 2003-05-19 MX MXPA04011203A patent/MXPA04011203A/es active IP Right Grant
- 2003-05-19 JP JP2004505045A patent/JP4545584B2/ja not_active Expired - Fee Related
-
2004
- 2004-04-23 US US10/830,071 patent/US7425571B2/en not_active Expired - Lifetime
-
2005
- 2005-02-15 US US11/059,027 patent/US20050143322A1/en not_active Abandoned
- 2005-02-15 US US11/058,981 patent/US20050137144A1/en not_active Abandoned
- 2005-08-15 HK HK05107036.6A patent/HK1074778A1/zh not_active IP Right Cessation
- 2005-09-07 US US11/222,135 patent/US20060009514A1/en not_active Abandoned
-
2006
- 2006-05-05 US US11/381,990 patent/US20080188476A1/en not_active Abandoned
-
2008
- 2008-09-05 US US12/205,769 patent/US7754748B2/en not_active Expired - Fee Related
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001026641A2 (en) * | 1999-10-13 | 2001-04-19 | Glaxo Group Limited | Morpholinol derivatives for the treatment of obesity |
Also Published As
Publication number | Publication date |
---|---|
US7425571B2 (en) | 2008-09-16 |
KR20050023265A (ko) | 2005-03-09 |
HK1074778A1 (zh) | 2005-11-25 |
AU2003231788B2 (en) | 2008-09-11 |
US20040198668A1 (en) | 2004-10-07 |
US20080188476A1 (en) | 2008-08-07 |
RU2004131636A (ru) | 2005-06-27 |
KR20110043664A (ko) | 2011-04-27 |
US20050143322A1 (en) | 2005-06-30 |
MXPA04011203A (es) | 2005-07-14 |
CA2483464C (en) | 2011-12-20 |
EP1505967B1 (en) | 2016-07-13 |
EP1505967A1 (en) | 2005-02-16 |
US20050137144A1 (en) | 2005-06-23 |
EP3173082A1 (en) | 2017-05-31 |
WO2003097046A1 (en) | 2003-11-27 |
US20060009514A1 (en) | 2006-01-12 |
JP2005530782A (ja) | 2005-10-13 |
RU2341259C2 (ru) | 2008-12-20 |
CN1652778A (zh) | 2005-08-10 |
US20080319036A1 (en) | 2008-12-25 |
US7754748B2 (en) | 2010-07-13 |
EP2301537A1 (en) | 2011-03-30 |
US20040033965A1 (en) | 2004-02-19 |
JP4545584B2 (ja) | 2010-09-15 |
EP1505967A4 (en) | 2007-09-05 |
US7109198B2 (en) | 2006-09-19 |
AU2003231788A1 (en) | 2003-12-02 |
CA2483464A1 (en) | 2003-11-27 |
CN1320886C (zh) | 2007-06-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101072885B1 (ko) | 비만치료방법 | |
US20150320726A1 (en) | Method for treating obesity | |
US7056890B2 (en) | Combination therapy for effecting weight loss and treating obesity | |
US8802636B2 (en) | Combination therapy for treatment of sleep apnea | |
US7553818B2 (en) | Combination therapy for effecting weight loss and treating obesity | |
US7659256B2 (en) | Combination therapy for effecting weight loss and treating obesity | |
US20190290618A1 (en) | Method for Treating Obesity | |
US20190262318A1 (en) | Method for Treating Obesity | |
CN110227083A (zh) | 一种含氯化钆和双胍类降糖药的药物组合物及其用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E90F | Notification of reason for final refusal | ||
A107 | Divisional application of patent | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20140923 Year of fee payment: 4 |
|
FPAY | Annual fee payment |
Payment date: 20150923 Year of fee payment: 5 |
|
FPAY | Annual fee payment |
Payment date: 20160923 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20170927 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20180927 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20190925 Year of fee payment: 9 |